News | MRI Breast | May 09, 2019

Screening MRI Detects BI-RADS 3 Breast Cancer in High-risk Patients

Study finds short-interval follow-up MRI may be appropriate for high-risk patients

Screening MRI Detects BI-RADS 3 Breast Cancer in High-risk Patients

May 9, 2019 — When appropriate, short-interval follow-up magnetic resonance imaging (MRI) can be used to identify early-stage breast cancer and avoid unnecessary biopsies, according to a new study. The findings were presented at the American Roentgen Ray Society (ARRS) 2019 Annual Meeting, May 5-10 in Honolulu.

Utilization of MRI for breast cancer screening continues to increase, as it is the most sensitive modality to detect breast cancer. Yet, much more is known about short-term follow-up of probably benign findings (<2 percent of malignancy) for mammography than MRI. The study was conducted to evaluate the frequency and cancer yield of American College of Radiology (ACR) Breast Imaging Reporting and Data System (BI-RADS) 3 lesions in patients undergoing baseline versus non-baseline high-risk screening MRI exams. Non-baseline MRI screening exams were defined as those preceded by at least one screening exam.

Among the 6,672 MRI screening exams performed in 3,214 patients included in the study, 202 (3 percent) were assigned a BI-RADS 3. Among baseline exams, 8.3 percent (82/983) were assigned BI-RADS 3, compared to 2.1 percent (120/5689) of non-baseline exams (p<0.01). Thirteen of 202 (6.4 percent) of the total BI-RADS 3 lesions yielded malignancy, with 12 of the 13 cancers described as either stage 0 or I at diagnosis. Out of 82 baseline exams, the cancer yield of BI-RADS 3 was 2 (2.4 percent), versus 11 of 120 (9.2 percent) on non-baseline exams (p=0.056). Of the 13 diagnosed cancers, eight were initially characterized as foci, three as non-mass enhancement and two as masses. Ten of 13 cancers were upgraded at the six-month follow-up MRI or before.

The results indicate BI-RADS 3 assessments are significantly more common in baseline versus non-baseline screening breast MRI exams, and BI-RADS 3 lesions on baseline exams have a lower cancer yield. Most cancers diagnosed on follow-up of BI-RADS 3 lesions are early stage and most are diagnosed at or before the six-month follow-up. The results indicate that when employed sensibly, short-interval follow-up MRI is an appropriate technique to identify early-stage breast cancer. "This study clarifies that probably benign assessments can be as useful for MRI as they are for mammography," said co-author Leslie Lamb, M.D., MSc, of Massachusetts General Hospital (MGH) and Harvard Medical School, both in Boston.

"Many patients and providers question the utility of BI-RADS 3 in MRI, particularly as some insurers do not cover the costs of the short interval follow-up MRIs. This study clarifies that short interval follow-up MRI is a valuable method of identifying early stage breast cancer while avoiding unnecessary biopsies." noted co-author Christine Edmonds, M.D., of the department of radiology at MGH.

For more information: www.arrs.org

Related Content

After receiving acupuncture treatment three days a week during the course of radiation treatment, head and neck cancer patients experienced less dry mouth, according to study results from researchers at The University of Texas MD Anderson Cancer Center

Image by Rudolf Langer from Pixabay 

News | Clinical Trials | December 06, 2019
December 6, 2019 — After receiving acupuncture treatment three days a week during the course of...
Timothy Whelan is a professor of oncology at McMaster University and a radiation oncologist at the Juravinski Cancer Centre of Hamilton Health Sciences. He holds a Canada Research Chair in Breast Cancer Research. Photo courtesy McMaster University

Timothy Whelan is a professor of oncology at McMaster University and a radiation oncologist at the Juravinski Cancer Centre of Hamilton Health Sciences. He holds a Canada Research Chair in Breast Cancer Research. Photo courtesy McMaster University. Photo courtesy of McMaster University

News | Breast Imaging | December 06, 2019
December 6, 2019 — A shorter course of higher-dose radiation treatment to part of the breast is showing promise in wo
 MRI system cardiac scan from DeBakey Hospital
News | Magnetic Resonance Imaging (MRI) | December 05, 2019
December 5, 2019 — The following is by Lawr
MRI Exablate neuro helmet from INSIGHTEC

MRI Exablate neuro helmet from INSIGHTEC. Image courtesy of Ali Rezai, M.D., and RSNA.

News | Clinical Trials | December 03, 2019
December 3, 2019 — Focused ultrasound is a safe and effective way to target and open areas of the blood-brain barrier
Image by Kira Hoffmann from Pixabay  #RSNA19

Image by Kira Hoffmann from Pixabay 

News | Clinical Trials | November 30, 2019
November 30, 2019 — Researchers are trying to identify injury patterns and predict future outcomes for victims of gun
#RSNA19 GE Healthcare introduced Serena Bright, the healthcare industry’s first contrast-enhanced mammography solution for biopsy
News | Mammography | November 30, 2019
November 30, 2019 — To help empower clinicians and patients in their fight against...
This bar graph shows breast cancer presentation by screening interval #RSNA19

This bar graph shows breast cancer presentation by screening interval. Image courtesy of study author and RSNA

News | Breast Imaging | November 28, 2019
November 28, 2019 — Cancers found in patients undergoing annual...
Prof. Dr. Samer Ezziddin from Saarland University/Saarland University Hospital.

Prof. Dr. Samer Ezziddin from Saarland University/Saarland University Hospital. Photo courtesy of Thorsten Mohr/Saarland University

News | Prostate Cancer | November 28, 2019
November 28, 2019 — Reports of new cancer treatments
News | Breast Imaging | November 26, 2019
November 26, 2019 — Unifi Workspace, a new comprehensive breast diagnostic reading solution from Hologic, will launch